E4r&D Sp. z o.o.

The trials here

What the 9 trials at this site are about, from their registry records.

Conditions

• Depression8 trials
• Schizophrenia1 trial

Phase

• Phase 24 trials
• Phase 33 trials
• Phase 2/31 trial
• Phase 41 trial

Status

• Completed5 trials
• Not yet recruiting2 trials
• Recruiting2 trials

Lead sponsor

• Seaport Therapeutics2 trials
• Angelini Pharma Italia Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A. Enunciabile Anche Angelini Pharma Italia S.p.A. Angelini Pharma S.p.A. A.C.R.A.F. S.p.A. Acraf S.p.A. Angelini S.p.A. aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A.1 trial
• HMNC Holding GmbH1 trial
• Mylan Inc.1 trial
• Neumora Therapeutics Inc.1 trial
• and 3 more

Running trials

• Not yet recruiting

  Evaluation of the efficacy of Trazodone in improving emotional blunting symptoms in Patients with Major Depressive Disorder

  2025-523267-38-00· Phase 4· Angelini Pharma Italia Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A. Enunciabile Anche Angelini Pharma Italia S.p.A. Angelini Pharma S.p.A. A.C.R.A.F. S.p.A. Acraf S.p.A. Angelini S.p.A. aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A.· Source

• Enrolling by invitation

  An Open-Label Extension Study to Evaluate the Safety and Tolerability of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 OLE Study)

  NCT07161700· Phase 2· Seaport Therapeutics· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)

  NCT07065240· Phase 2· Seaport Therapeutics· Source

• Recruiting

  A research study to compare the antidepressant ability and safety of Samyr® tablets versus placebo tablets as an adjunct to additional antidepressant treatment in patients with major depressive disorder (MDD)

  2024-513019-29-00· Phase 3· Mylan Inc.· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Depression4 recruiting

Closed trials

• Completed

  A 14-week, multicentre, double-blind, randomised, placebo-controlled phase II study with an 8-week treatment period to assess the efficacy and tolerability of a fixed dose of BH-200 (250 mg BID) in outpatients with Major Depressive Disorder (MDD)

  2024-513104-34-00· Phase 2· HMNC Holding GmbH· Source

• Completed

  Long-term Study to Assess the Safety and Effectiveness of NMRA-335140 in Participants with Major Depressive Disorder

  NCT06029439· Phase 3· Neumora Therapeutics Inc.· Source

• Completed

  Study to Assess the Effects of Oral NMRA-335140 in Participants With Major Depressive Disorder

  NCT06058039· Phase 3· Neumora Therapeutics, Inc.· Source

• Completed

  Protocol Lay Person Short Title: A Trial of the Safety and Efficacy of Flexible Doses of SEP-363856 as Adjunctive Therapy in the Treatment of Adults with Major Depressive Disorder.

  2022-500538-27-00· Phase 2/3· Otsuka Pharmaceutical Development And Commercialization Inc.· Source

• Completed

  A Study to Evaluate RL-007 in the Treatment of Cognitive Impairment Associated With Schizophrenia (CIAS)

  NCT05686239· Phase 2· Recognify Life Sciences· Source